The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Lauer and Walker, N Engl J Med 345(1):41-52 July 5, 2001.

Correspondence
PreviousPrevious
Volume 345:1425-1428 November 8, 2001 Number 19
NextNext

Hepatitis C Virus Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Lauer, G. M.
-PubMed Citation
To the Editor: In their article on hepatitis C virus (HCV) infection (July 5 issue),1 Lauer and Walker note that the pegylated interferon peginterferon alfa-2a has been approved by the Food and Drug Administration (FDA), when in fact it is peginterferon alfa-2b that has received FDA approval. Large studies in the United States and Europe of the use of either brand of pegylated interferon plus ribavirin have been completed and found sustained virologic response rates of 56 percent and 61 percent.2,3 The combination of peginterferon alfa-2b plus ribavirin has been approved in Europe and is expected to be approved soon . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.